XML 56 R41.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Earnings Per Share [Abstract] |
Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders | The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Net loss attributable to Adaptive Biotechnologies Corporation |  | $ | (225,250 | ) |  | $ | (200,191 | ) |  | $ | (207,279 | )
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  |  | 144,383,294 |  |  |  | 142,515,917 |  |  |  | 140,354,915 |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  | $ | (1.56 | ) |  | $ | (1.40 | ) |  | $ | (1.48 | )
Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share | The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021, as they had an anti-dilutive effect:
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Stock options outstanding |  |  | 13,839,067 |  |  |  | 13,892,287 |  |  |  | 13,097,374 |
Nonvested restricted stock units outstanding |  |  | 9,630,579 |  |  |  | 4,799,850 |  |  |  | 693,173 |
Maximum nonvested market-based restricted stock units outstanding eligible to be earned |  |  | 1,663,961 |  |  |  | 410,282 |  |  |  | — |
Common stock warrant outstanding |  |  | — |  |  |  | — |  |  |  | 8,570 |
Total |  |  | 25,133,607 |  |  |  | 19,102,419 |  |  |  | 13,799,117 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration